EA202190802A3 - Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1 - Google Patents

Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1

Info

Publication number
EA202190802A3
EA202190802A3 EA202190802A EA202190802A EA202190802A3 EA 202190802 A3 EA202190802 A3 EA 202190802A3 EA 202190802 A EA202190802 A EA 202190802A EA 202190802 A EA202190802 A EA 202190802A EA 202190802 A3 EA202190802 A3 EA 202190802A3
Authority
EA
Eurasian Patent Office
Prior art keywords
glp
receptor agonist
compound
agonist effect
pyrazolopyridine derivatives
Prior art date
Application number
EA202190802A
Other languages
English (en)
Other versions
EA202190802A2 (ru
Inventor
Хитоси Йосино
Сатоси Цутия
Ацуси Мацуо
Цутому Сато
Масахиро Нисимото
Киоко Огури
Хироко Огава
Йосикадзу Нисимура
Йосиюки Фурута
Хиротака Касиваги
Нобуюки Хори
Такума Камон
Такуя Сирайси
Сосин Йосида
Такахиро Кавай
Сатоси Танида
Масахиде Аоки
Original Assignee
Тюгай Сэяку Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тюгай Сэяку Кабусики Кайся filed Critical Тюгай Сэяку Кабусики Кайся
Publication of EA202190802A2 publication Critical patent/EA202190802A2/ru
Publication of EA202190802A3 publication Critical patent/EA202190802A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

Данное изобретение предлагает соединение, имеющее основную структуру, проиллюстрированную формулой (I), в которой индольное кольцо и фрагмент пиразолопиридина соединены через заместитель, его соль или сольват, либо соединения, либо соли соединения, а также профилактическое средство или лекарственное средство для лечения инсулиннезависимого сахарного диабета (диабет типа 2) или ожирения, содержащее такое соединение, соль или сольват в качестве действующего вещества.
EA202190802A 2016-09-26 2017-09-26 Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1 EA202190802A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016187605 2016-09-26

Publications (2)

Publication Number Publication Date
EA202190802A2 EA202190802A2 (ru) 2021-07-30
EA202190802A3 true EA202190802A3 (ru) 2021-10-29

Family

ID=61689595

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202190802A EA202190802A3 (ru) 2016-09-26 2017-09-26 Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1
EA201990518A EA037989B1 (ru) 2016-09-26 2017-09-26 Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201990518A EA037989B1 (ru) 2016-09-26 2017-09-26 Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1

Country Status (32)

Country Link
US (3) US10858356B2 (ru)
EP (3) EP4134367A1 (ru)
JP (4) JP6567778B2 (ru)
KR (1) KR102223227B1 (ru)
CN (1) CN109790161B (ru)
AU (4) AU2017330733B2 (ru)
BR (1) BR112019005322A2 (ru)
CA (1) CA3038479C (ru)
CL (1) CL2019000663A1 (ru)
CO (1) CO2019002595A2 (ru)
CR (1) CR20190149A (ru)
DK (1) DK3517538T3 (ru)
DO (1) DOP2019000074A (ru)
EA (2) EA202190802A3 (ru)
EC (1) ECSP19020228A (ru)
FI (1) FI3517538T3 (ru)
IL (2) IL264945B (ru)
JO (1) JOP20190060A1 (ru)
LT (1) LT3517538T (ru)
MA (1) MA46286A (ru)
MX (2) MX2019003488A (ru)
PE (1) PE20190709A1 (ru)
PH (1) PH12019500659A1 (ru)
PT (1) PT3517538T (ru)
RS (1) RS65398B1 (ru)
SA (1) SA519401409B1 (ru)
SG (1) SG11201901565VA (ru)
TN (1) TN2019000054A1 (ru)
TW (1) TWI753946B (ru)
UA (1) UA125586C2 (ru)
WO (1) WO2018056453A1 (ru)
ZA (1) ZA201901070B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
CA3081399A1 (en) * 2017-11-02 2019-05-09 Aicuris Gmbh & Co. Kg Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
JP7461104B2 (ja) 2017-11-29 2024-04-03 中外製薬株式会社 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
JP7360301B2 (ja) 2019-11-08 2023-10-12 Kyb株式会社 作動流体供給システム
CA3169975A1 (en) 2020-02-07 2021-08-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
WO2021249492A1 (zh) * 2020-06-10 2021-12-16 南京明德新药研发有限公司 甲基取代的苯并二噁唑类化合物及其应用
PE20230854A1 (es) * 2020-07-20 2023-05-29 Eccogene Shanghai Co Ltd Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos
JP2023537501A (ja) * 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環glp-1アゴニスト
EP4204415A1 (en) 2020-08-28 2023-07-05 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2022007979A1 (zh) 2020-09-01 2022-01-13 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
US20230322771A1 (en) * 2020-09-07 2023-10-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN116348464A (zh) 2020-10-12 2023-06-27 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
CA3200245A1 (en) 2020-11-27 2022-06-02 Junjun Wu Benzimidazole derivative and preparation method therefor and medical use thereof
EP4317142A1 (en) 2021-03-22 2024-02-07 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Thiophene glp-1 receptor agonist and use thereof
WO2022202864A1 (ja) 2021-03-24 2022-09-29 塩野義製薬株式会社 縮合環を有するglp-1受容体作動薬を含有する医薬組成物
CN117362283A (zh) 2021-06-24 2024-01-09 杭州中美华东制药有限公司 Glp-1受体激动剂及其组合物和用途
WO2023016546A1 (en) * 2021-08-12 2023-02-16 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CA3231153A1 (en) 2021-09-08 2023-03-16 Kosuke Takemoto Medicine for prevention and treatment of diseases linked to anti-obesity activity
WO2023138684A1 (en) * 2022-01-24 2023-07-27 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023151574A1 (en) * 2022-02-09 2023-08-17 Gasherbrum Bio Inc. Heterocyclic glp-1 agonists
WO2023220109A1 (en) 2022-05-11 2023-11-16 Eli Lilly And Company Glp1 pharmaceutical compositions
WO2023220112A1 (en) 2022-05-11 2023-11-16 Eli Lilly And Company Glp1 tablet compositions
CN116003403A (zh) * 2022-11-20 2023-04-25 药康众拓(北京)医药科技有限公司 一种氘代吲唑类化合物、药物组合物及其应用
CN117447493A (zh) * 2023-12-25 2024-01-26 药康众拓(北京)医药科技有限公司 氘代吲哚嗪类化合物、药物组合物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998438A (en) 1996-11-26 1999-12-07 Allelix Biopharmaceuticals, Inc. 5-cyclo indole compounds
UA66842C2 (ru) 1998-04-01 2004-06-15 Янссен Фармацевтика Н.В. Производные пиридина как ингибиторы pde iv
ZA200500782B (en) * 2002-08-26 2007-10-31 Takeda Pharmaceutical Calcium receptor modulating compound and use thereof
CA2494700C (en) 2002-08-26 2011-06-28 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
DE10360774A1 (de) 2003-12-23 2005-07-28 Robert Bosch Gmbh Verfahren zur Herstellung eines Brennstoffeinspritzventils und Brennstoffeinspritzventil
WO2006048727A1 (en) 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
JP2010510987A (ja) 2006-11-27 2010-04-08 ハー・ルンドベック・アクチエゼルスカベット ヘテロアリールアミド誘導体
CN101959405B (zh) 2008-03-07 2014-07-02 转化技术制药有限责任公司 治疗糖尿病的氧杂二氮杂蒽化合物
RU2015105591A (ru) 2008-06-10 2015-08-10 Эббви Инк. Новые трициклические соединения
JP5755217B2 (ja) 2009-03-30 2015-07-29 トランステック・ファーマ,エルエルシー 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
JP5802898B2 (ja) * 2009-07-09 2015-11-04 ラクオリア創薬株式会社 消化管運動異常が関与する疾患を治療するためのアシッドポンプ拮抗剤
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
CN103874702B (zh) 2011-07-15 2015-12-09 杨森制药公司 作为γ分泌酶调节剂的经取代的吲哚衍生物
EP2953681B1 (en) * 2013-02-06 2017-03-15 Boehringer Ingelheim International GmbH New indanyloxydihydrobenzofuranylacetic acids
CN103086955B (zh) 2013-02-19 2014-10-15 中国医学科学院医药生物技术研究所 3-氨基-4-烷氧亚胺基哌啶的制备方法
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
EP2993174A1 (en) * 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1

Also Published As

Publication number Publication date
DK3517538T3 (da) 2024-03-25
EA202190802A2 (ru) 2021-07-30
EP3517538A4 (en) 2020-06-10
JP6567778B2 (ja) 2019-08-28
US11814381B2 (en) 2023-11-14
CN109790161B (zh) 2022-03-11
EA201990518A1 (ru) 2019-12-30
CA3038479C (en) 2021-06-22
EA037989B1 (ru) 2021-06-21
AU2022205222A1 (en) 2022-08-04
IL264945B (en) 2021-10-31
MA46286A (fr) 2019-07-31
UA125586C2 (uk) 2022-04-27
LT3517538T (lt) 2024-05-10
CN109790161A (zh) 2019-05-21
CR20190149A (es) 2019-08-27
PT3517538T (pt) 2024-04-09
WO2018056453A1 (ja) 2018-03-29
AU2017330733B2 (en) 2020-05-28
AU2024201884A1 (en) 2024-04-11
MX2019003488A (es) 2019-12-16
JPWO2018056453A1 (ja) 2019-07-11
JP2023100963A (ja) 2023-07-19
JP2019203015A (ja) 2019-11-28
DOP2019000074A (es) 2019-05-31
US20210017176A1 (en) 2021-01-21
AU2017330733A1 (en) 2019-03-14
CA3038479A1 (en) 2018-03-29
SG11201901565VA (en) 2019-03-28
TN2019000054A1 (en) 2020-07-15
AU2020223687A1 (en) 2020-09-10
TW201827426A (zh) 2018-08-01
IL264945A (en) 2019-05-30
AU2020223687B2 (en) 2022-04-14
US20230382912A1 (en) 2023-11-30
US20190225604A1 (en) 2019-07-25
EP3517538A1 (en) 2019-07-31
PH12019500659A1 (en) 2019-12-16
JP6957564B2 (ja) 2021-11-02
PE20190709A1 (es) 2019-05-17
KR20190039591A (ko) 2019-04-12
FI3517538T3 (fi) 2024-05-20
IL287166A (en) 2021-12-01
TWI753946B (zh) 2022-02-01
ZA201901070B (en) 2021-06-30
ECSP19020228A (es) 2019-06-30
JP2022003087A (ja) 2022-01-11
JP7280929B2 (ja) 2023-05-24
KR102223227B1 (ko) 2021-03-08
SA519401409B1 (ar) 2022-04-07
AU2022205222B2 (en) 2024-04-04
EP3517538B1 (en) 2024-03-13
MX2022004071A (es) 2022-05-03
US10858356B2 (en) 2020-12-08
RS65398B1 (sr) 2024-04-30
EP4134367A1 (en) 2023-02-15
EP4349840A2 (en) 2024-04-10
CL2019000663A1 (es) 2019-07-26
JOP20190060A1 (ar) 2019-03-26
BR112019005322A2 (pt) 2019-07-02
NZ751725A (en) 2021-03-26
CO2019002595A2 (es) 2019-03-29

Similar Documents

Publication Publication Date Title
EA202190802A3 (ru) Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
PE20191143A1 (es) Nuevos compuestos como agonistas peptidicos trigonales de los receptores de glp1/glucagon/gip
EA201992679A1 (ru) N-замещенные индольные производные
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
RU2017118335A (ru) Гетероциклическое производное, обладающее активирующей ampk активностью
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
RU2017117559A (ru) Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
EA201692300A1 (ru) Производные карбоксамида
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
TW201613914A (en) 2-acylaminothiazole derivative or salt thereof
EA202090995A1 (ru) Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety
EA202090925A1 (ru) Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
BR112022008647A2 (pt) Composto de imidazolidinona, método de preparação do mesmo e uso do mesmo
EA201891691A1 (ru) Асимметричные бензолсульфонилмочевины и их применение в медицине
TH1801004568A (th) อนุพันธ์เฮเทอโรไซคลิคซัลโฟนาไมด์และยาซึ่งมีสารดังกล่าว
TH1901001721A (th) อนุพันธ์ไพราโซโลไพริดีนที่มีผลที่มีผลของglp-1รีเซพเตอร์อะโกนิสต์
PH12019501027A1 (en) Therapeutic drug or prophylactic drug for diabetic nephropathy
EA202091302A1 (ru) Замещенные азабициклы в качестве положительных аллостерических модуляторов мускаринового рецептора m1